Structural biology of recombinant bovine pancreatic phospholipase A2 and its inhibitor complexes

Current Topics in Medicinal Chemistry

Volumn 7, Issue 8, 2007, Pages 779-785

  Sekar, K ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Drug inhibitor molecules; Extra cellular; Inflammation and rheumatoid arthitis; Phospholipase A2; Surface loop; X ray crystallography

Indexed keywords

1 HEXADECYL 3 (TRIFLUOROETHYL) SN GLYCERO 2 PHOSPHOMETHANOL; 1 O OCTYL 2 HEPTYLPHOSPHONYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; ANISIC ACID; CALCIUM ION; FATTY ACID; LYSOPHOSPHOLIPID; MJ 33; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPID; RECOMBINANT BOVINE PANCREAS PHOSPHOLIPASE A2 INHIBITOR; UNCLASSIFIED DRUG; WATER;

CATALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ANIMALS; BINDING SITES; CATTLE; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MUTATION; PANCREAS; PHOSPHOLIPASES A; RECOMBINANT PROTEINS;

EID: 34247632210     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780487632     Document Type: Review

References (45)

1. 2 from snake venom to human secreted forms. J. Mol. Evol. 1990, 31(3), 228-238.
2. 2. J. Biol. Chem. 1994, 269(18), 13057-13060.
3. 2. Annu. Rev. Biochem. 1995, 64, 653-688.
4. 2: More than electrostatics and a major role for tryptophan. Curr. Opin. Struct Biol. 1999, 9(4), 428-432.
5. 2. Adv. Protein Chem. 1994, 45, 53-88.
6. 2 at 2.2 Å resolution. Nature 1991, 352(6330), 79-82.
7. 2 at 1.7Å resolution. J. Mol. Biol. 1981, 147, 97-123.
8. 2-paradigm. Chem. Rev. 2001, 101(9), 2613-2654.
9. 2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr. 2002, D58, 1813-9.
10. 2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7 Å crystal structure. Biochemistry 2002, 41(36), 10914-10919.
11. 2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8 Å resolution. J. Biol. Chem. 2002 277(43), 41079-41085.
12. 2 and alpha-tocopherol at 1.8 Å resolution. J. Mol. Biol. 2002, 320(2), 215-222.
13. 2 and a highly potent inhibitor (FPL67047XX). J. Med. Chem. 1996, 39(20), 3878-3881.
14. 2 and diclofenac at 2.7 A resolution. Acta Crystallogr. 2006, D62, 410-416.
15. 2. Science 1990, 250(4987), 1541-1546.
16. 2 in a complex with a transition-state analogue. Science 1990, 250(4987), 1563-1566.
17. 2 from inflammatory exudate. Science 1991, 254(5034), 1007-1010.
18. 2 with the inhibitor 1-Hexadecyl-3-(trifluoroethyl)- sn-glycero-2-phosphomethanol. Biochemistry 1997, 36(46), 14186-14191.
19. 2 with a transition-state analogue. Acta Crystallog., 1998, D54 334-341.
20. 2. J. Mol. Biol. 2003, 333(2), 367-376.
21. 2. Acta Crystallogr. 2006, D62, 392-397.
22. 2 complexed with a substrate-derived inhibitor. Nature 1990, 347(6294), 689-691.
23. 2 in a complex with a transition-state analogue. Science 1990, 250(4987), 1560-1563.
24. 2: Absence of the conserved structural water. Protein Sci. 1994, 3(11), 2082-2088.
25. 2 engineering. Structural and functional roles of the highly conserved active site residue aspartate-99. Biochemistry 1997, 36(11), 3104-3114.
26. 2. Acta Crystallogr. 1999, D55, 46-50.
27. 2. J. Mol. Biol. 2002, 324(4), 755-762
28. 2. Acta Crystallogr. 2006, F62, 1-5.
29. 2. Acta Crystallogr. 2005, F61, 3-7.
30. Harding, M. M. The geometry of metal-ligand interactions relevant to proteins. Acta Crystallogr. 1999, D55, 1432-1443.
31. 2. Eur. J. Biochem. 1989, 182(2), 307-313.
32. 2 with micellar interfaces. The role of the N-terminal region. Biochemistry 1975, 14(25), 5387-5394.
33. 2 engineering. Deletion of C-terminus segment changes substrate specificity and uncouples calcium and substrate binding at the zwitterionic interface. Biochemistry 1996, 35(37), 12164-12174.
34. 2. Acta Crystallogr. 1998, D54, 342-346.
35. 2. Acta Crystallogr. 1999, D55 443-447.
36. 2: Increased hydrophobic interactions of the phenyl groups compensate for the disrupted hydrogen bonds of the tyrosines. Protein Sci. 1992, 1(12), 1585-1594.
37. 2. Biochemistry 2000, 39(40), 12312-12323.
38. 2: Novel transition-state analogues. Biochemistry 1991, 30(42), 10256-10268.
39. 2 inhibit release of free arachidonate in thrombin-stimulated human platelets. J. Biol. Chem. 1994, 269(22), 15625-15630.
40. 2 decreases surfactant phosphatidylcholine degradation by the rat lung. Biochem. J. 1992, 288, 407-411.
41. Homan, R.; Krause, B. R. Established and emerging strategies for inhibition of cholesterol absorption. Curr. Pharm. Design 1997, 3, 29-44.
42. Kim, N.; Sohn, U. D.; Mangannan, V.; Rich, H.; Jain, M. K.; Behar, J.; Biancani, P. Leukotrienes in acetylcholine-induced contraction of esophageal circular smooth muscle in experimental esophagitis. Gastroenterology 1997, 112(5), 1548-1558.
43. 2 activity is required for permeability barrier homeostasis. J. Invest Dermatol. 1996, 106, 57-63
44. 2-n-dodecyl-phosphorylcholine complex. Proteins 1994, 19(4), 330-339.
45. 2. J. Am. Chem. Soc. 1988, 110, 2665-2666.